1. This substance refers to a solid pharmaceutical component, including one or more acceptable pre pharmacists, and an active pharmaceutical component ( ldqoe； API rdque；),It is a compound of formula (1) or (2),or a pharmacologically acceptable salt, solvate, or hydrate thereof, wherein the active pharmaceutical ingredient (API) is not exposed to a basic compound. Claim 1: A solid phase pharmaceutical composition, which comprises one or more pharmaceutically acceptable excipients, and an active pharmaceutical ingredient (API),It is a compound of formula (1) or (2),Or a pharmaceutically acceptable salt, solution or hydrate in which the active medicinal material (API) is not exposed to a basic compound, namely: A is cor5, OPO (or5) 2, Po (or5) 2so2or5, por5 or 1h-tetrazol-5-ilo, wherein R5 is h or a group of polyester； W is link, c1-3 tar, or alquenileno C2-3； and arilo. C6-10, or optional c3-9 heteromorphic reaction, from 1 to 3 from halogen, NO2, C1-6 tar, alcoxyl C1-6, C1-6 tar replaced by halogen and C1-6 tar replaced by halogen；Z is selected from formula group (3), where the asterisk of Z represents the aggregation point between - C (R3) - (R4) and formula group (1) or (2),respectively； R6 is selected from hydrogen and C1-6alkyl； and J1 and J2 are independently methylene or a heteroatom selected from S, O and NR5； wherein R5 is selected from hydrogen and C1-6alkyl； and any alkylene in Z may be further substituted by one to three radicals selected from halogen, hydroxyl, C1-6alkyl: or R6 may be attached to a carbon atom of Y to form a 5-7 membered ring； R1 is C6-10 aryl, or C3-9 heteroaryl optionally substituted by C1-6 alkyl, C6-10 aryl, C6-10 aryl-C1-4 alkyl, C3-9 heteroaryl, C3-9 heteroaryl-C1-4 alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-4alkyl,C3-8 heterocycloalkyl, or C3-8 heterocycloalkyl-C1-4alkyl； wherein any aryl, heteroaryl, cycloalkyl, or heterocycloalkyl of R1 may be substituted by 1 to 5 groups selected from halogen, C1-6 alkyl, C1-6 alkoxy, and C1-6 a
